Table 3 In vivo IFN-ү production induced by the chosen liposome formulations.
Study 1 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liposome | IFN-γ production1 | IFN-γ production (% of DDA:TDB) | In vivo strength | IFN-γ production2 | IFN-γ production (% of DDA:TDB) | In vivo strength | IFN-γ production3 | IFN-γ production (% of DDA:TDB) | In vivo strength | |||
DDA:TDB | ~ 4 ng/ml | 100% | +++ > 80% (> 3.2 ng/ml) | 140 ng/ml | 100% | +++ > 80% (112 ng/ml) | > 20 ng/ml | 100% | +++ > 80% (16 ng/ml) | |||
DDA:DSPC:TDB | ~ 2.5 ng/ml | 63% | ++50–79% (> 3.2 ng/ml) | |||||||||
DDA:DSPC:TDB (50%) | ~ 1.5 ng/ml | 38% | + < 50% (< 2 ng/ml) | |||||||||
DSPC:TDB | < 1 ng/ml (NS to Ag alone) | 25% | + < 50% (< 2 ng/ml) | < 5 ng/ml (NS to Ag alone) | 25% | + < 50% (10 ng/ml) | ||||||
DOTAP:TDB | 20 ng/ml | 14% | + < 50% (70 ng/ml) | |||||||||
DC-Chol:TDB | 20 ng/ml | 14% | + < 50% (70 ng/ml) | |||||||||
Study 2 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liposome | IFN-γ production1 | % of DDA:TDB | In vivo strength | IFN-γ production2 | % of DDA:TDB | In vivo strength | IFN-γ production3 | % of DDA:TDB | In vivo strength | IFN-γ production4 | % of DDA:TDB | In vivo strength |
DDA:TDB | ~ 1.8 ng/ml | 100% | +++ > 80% (1.44 ng/ml) | ~ 1.6 ng/ml | 100% | +++ > 80% (1.28 ng/ml) | ~ 110 ng/ml | 100% | +++ > 80% (88 ng/ml) | ~ 100 ng/ml | 100% | +++ > 80% (80 ng/ml) |
DDA alone | ~ 20 ng/ml | 18% | + < 50% (55 ng/ml) | ~ 20 ng/ml | 20% | + < 50% (50 ng/ml) | ||||||
DDA:TDB:PEG25% | ~ 0.5 ng/ml | 28% | + < 50% (< 0.9 ng/ml) | |||||||||
DDA:CHOL18:TDB | ~ 1.2 ng/ml | 75% | ++50–79% (0.8 ng/ml) | |||||||||
DDA:CHOL31:TDB | ~ 0.8 ng/ml | 50% | ++50–79% (0.8 ng/ml) | |||||||||
